Market Place
Sourcing Support
Secura Bio`s Copiktra Data in Relapsed T-cell Lymphoma at ASH 2024
09 Dec 2024 //
GLOBENEWSWIRE
Secura Bio Presents Combination Data of COPIKTRA® at ASH 2024
09 Dec 2024 //
GLOBENEWSWIRE
Secura Bio Appoints Dr. Patrick as Chairman of Board of Directors
14 Nov 2024 //
GLOBENEWSWIRE
Secura Bio to Present Copiktra® Data at ASH 2024
06 Nov 2024 //
GLOBENEWSWIRE
Secura Bio Announces the Addition of Two New Board of Directors Members
07 Dec 2023 //
PR NEWSWIRE
Secura Bio to keep offering blood cancer drug despite negative ODAC vote
23 Mar 2023 //
ENDPTS
Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib
09 Jan 2023 //
PR NEWSWIRE
FDA adcomm takes down Secura Bio`s leukemia drug after trial results
23 Sep 2022 //
ENDPTS
FDA threatens to clamp down on another PI3K blood cancer drug—a full approval
23 Sep 2022 //
FIERCEPHARMA
FDA puts the microscope on 2 more cancer approvals without voluntary withdrawals
23 Jul 2022 //
FIERCEPHARMA
PI3K inhibitor hit with an increased death risk warning from FDA
01 Jul 2022 //
ENDPTS
SECURA BIO ANNOUNCES PRESENTATION OF COPIKTRA DATA FOR PTCL
14 Dec 2021 //
PRNEWSWIRE
Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma
03 Dec 2021 //
PRNEWSWIRE
Secura Bio Announces Voluntary U.S. Withdrawal Of The r/r Follicular Lymphoma
03 Dec 2021 //
PRNEWSWIRE
FDA`s ODAC to review accelerated approvals for multiple myeloma, leukemia
24 Sep 2021 //
ENDPTS
COPIKTRA® (duvelisib) Receives EMA for the Treatment
09 Jun 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.